In silico screening-based discovery of novel covalent inhibitors of the SARS-CoV-2 3CL protease

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CL protease (3CL(pro)) has been regarded as an extremely promising antiviral target for the treatment of coronavirus disease 2019 (COVID-19). Here, we carried out a virtual screening based on commercial compounds database to find nove...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiong, Muya, Nie, Tianqing, Shao, Qiang, Li, Minjun, Su, Haixia, Xu, Yechun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783839/
https://www.ncbi.nlm.nih.gov/pubmed/35114541
http://dx.doi.org/10.1016/j.ejmech.2022.114130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8783839/
https://www.ncbi.nlm.nih.gov/pubmed/35114541
http://dx.doi.org/10.1016/j.ejmech.2022.114130

Ejemplares similares